Dujmovic, Irena (6701590899)Irena (6701590899)DujmovicMader, Simone (35364763800)Simone (35364763800)MaderSchanda, Kathrin (6507128371)Kathrin (6507128371)SchandaDeisenhammer, Florian (7004758773)Florian (7004758773)DeisenhammerStojsavljevic, Nebojsa (6603086728)Nebojsa (6603086728)StojsavljevicKostic, Jelena (57159483500)Jelena (57159483500)KosticBerger, Thomas (7202632707)Thomas (7202632707)BergerDrulovic, Jelena (55886929900)Jelena (55886929900)DrulovicReindl, Markus (56062617100)Markus (56062617100)Reindl2025-07-022025-07-022011https://doi.org/10.1016/j.jneuroim.2011.01.007https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955657783&doi=10.1016%2fj.jneuroim.2011.01.007&partnerID=40&md5=42dd52f0568c990aeab6060e7fd78b8dhttps://remedy.med.bg.ac.rs/handle/123456789/14102Neuromyelitis optica spectrum disorders (NMOSD) are associated with anti-aquaporin-4 autoantibodies (AQP4-IgG). Limited data is available on longitudinal cerebrospinal fluid (CSF) AQP4-IgG and their relation to disease activity and inflammatory parameters. AQP4-IgG titers were measured in matched longitudinal serum and CSF samples of 12 patients with NMOSD by an immunofluorescence assay and correlated with clinical parameters. CSF AQP4-IgG were present in patients with high serum titers and correlated with spinal MRI lesion length and CSF parameters. Clinical improvement was associated with a decrease in CSF, but not serum, AQP4-IgG titers. Thus, CSF AQP4-IgG were associated with clinical activity and neuroinflammation. © 2011 Elsevier B.V.Aquaporin-4Cerebrospinal fluidClinical activityLongitudinal studyNeuromyelitis optica